A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

In this Monday edition of quantum computing news, we look at a new push by SEALSQ ($LAES) to build silicon-based quantum systems, Xanadu’s early ...

ZK-SQL executes SQL queries and generates zero-knowledge proofs that verify correctness without revealing underlying data. Built on Goldilocks field arithmetic and FRI-based proving. Data layer ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer—has long captured the public imagination. Yet most arguments about it rest ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

DNA Ginkgo Bioworks Holdings, Inc.

Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...